Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination medication containing pantoprazole, amoxicillin, and clarithromycin. It is used for the eradication of *Helicobacter pylori* (*H. pylori*) infection.
## Primary Indications
* Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
* **Sompraz HP:** One dose pack should be taken twice daily for 10 to 14 days. Each dose pack typically contains pantoprazole 40 mg, amoxicillin 500 mg, and clarithromycin 500 mg. The exact composition of the dose pack may vary.
## Pediatric Dosing
* Pediatric dosing is not established for Sompraz HP. Dosing of individual components should be determined based on age, weight, and infection severity.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically needed for pantoprazole. Amoxicillin and clarithromycin may require dose adjustment in severe renal impairment. Consult specific product information for amoxicillin and clarithromycin.
* **Hepatic Impairment:** Pantoprazole may require dose adjustment in severe hepatic impairment. Consult specific product information for clarithromycin.
## Contraindications
* Hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of hypersensitivity to penicillin or other beta-lactam antibiotics.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Concomitant use with certain medications (e.g., cisapride, pimozide, terfenadine, astemizole, ergotamine).
* Severe renal impairment with co-administration of clarithromycin and certain CYP3A4 substrates.
## Adverse Effects
* **Common:** Diarrhea, nausea, headache, abdominal pain, dizziness, rash.
* **Serious:** *Clostridium difficile*-associated diarrhea, anaphylaxis, severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), QT prolongation (clarithromycin), hepatic dysfunction, electrolyte imbalances.
## Key Drug Interactions
* **Pantoprazole:** May decrease the absorption of drugs requiring gastric acidity (e.g., ketoconazole, itraconazole, posaconazole, iron salts, vitamin B12). May affect the metabolism of certain CYP2C19 substrates.
* **Amoxicillin:** May decrease the effectiveness of oral contraceptives. Probenecid may increase and prolong blood levels of amoxicillin.
* **Clarithromycin:** Potent inhibitor of CYP3A4. Can increase plasma concentrations of drugs metabolized by CYP3A4 (e.g., warfarin, carbamazepine, theophylline, simvastatin, lovastatin, certain calcium channel blockers, certain HIV protease inhibitors, sildenafil). Increased risk of myopathy and rhabdomyolysis with statins. May increase the risk of QT prolongation with other QT-prolonging drugs.
## Monitoring
* Signs and symptoms of *H. pylori* eradication (e.g., resolution of ulcer symptoms).
* Monitor for signs of hypersensitivity reactions.
* Monitor for diarrhea, especially *C. difficile*-associated diarrhea.
* Monitor for signs of liver dysfunction.
* Consider ECG monitoring if risk factors for QT prolongation are present, especially when co-administered with other QT-prolonging agents.
## Clinical Pearls
* Ensure the patient is not allergic to penicillin before initiating amoxicillin.
* Advise patients to complete the full course of therapy, even if symptoms improve.
* Take pantoprazole as prescribed, usually before a meal.
* For patients with known macrolide resistance in their geographic area, alternative therapies may be considered.
* The combination product simplifies adherence but requires careful consideration of individual component contraindications and interactions.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and local guidelines for complete and up-to-date details before making any clinical decisions.
